Literature DB >> 27803355

Past and Present ARDS Mortality Rates: A Systematic Review.

Jan Máca1,2, Ondřej Jor3, Michal Holub4, Peter Sklienka3,2, Filip Burša3,2, Michal Burda5, Vladimír Janout6, Pavel Ševčík3,2.   

Abstract

ARDS is severe form of respiratory failure with significant impact on the morbidity and mortality of critical care patients. Epidemiological data are crucial for evaluating the efficacy of therapeutic interventions, designing studies, and optimizing resource distribution. The goal of this review is to present general aspects of mortality data published over the past decades. A systematic search of the MEDLINE/PubMed was performed. The articles were divided according to their methodology, type of reported mortality, and time. The main outcome was mortality. Extracted data included study duration, number of patients, and number of centers. The mortality trends and current mortality were calculated for subgroups consisting of in-hospital, ICU, 28/30-d, and 60-d mortality over 3 time periods (A, before 1995; B, 1995-2000; C, after 2000). The retrospectivity and prospectivity were also taken into account. Moreover, we present the most recent mortality rates since 2010. One hundred seventy-seven articles were included in the final analysis. General mortality rates ranged from 11 to 87% in studies including subjects with ARDS of all etiologies (mixed group). Linear regression revealed that the study design (28/30-d or 60-d) significantly influenced the mortality rate. Reported mortality rates were higher in prospective studies, such as randomized controlled trials and prospective observational studies compared with retrospective observational studies. Mortality rates exhibited a linear decrease in relation to time period (P < .001). The number of centers showed a significant negative correlation with mortality rates. The prospective observational studies did not have consistently higher mortality rates compared with randomized controlled trials. The mortality trends over 3 time periods (before 1995, 1995-2000, and after 2000) yielded variable results in general ARDS populations. However, a mortality decrease was present mostly in prospective studies. Since 2010, the overall rates of in-hospital, ICU, and 28/30-d and 60-d mortality were 45, 38, 30, and 32%, respectively.
Copyright © 2017 by Daedalus Enterprises.

Entities:  

Keywords:  ARDS; acute lung injury; clinical trial; mortality; outcome

Mesh:

Year:  2016        PMID: 27803355     DOI: 10.4187/respcare.04716

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  94 in total

1.  Delayed Akt suppression in the lipopolysaccharide-induced acute lung injury promotes resolution that is associated with enhanced effector regulatory T cells.

Authors:  Sandeep Artham; Arti Verma; Abdulrahman Alwhaibi; Mir S Adil; Santhakumar Manicassamy; David H Munn; Payaningal R Somanath
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-02-19       Impact factor: 5.464

2.  Bronchoalveolar fluid and plasma inflammatory biomarkers in contemporary ARDS patients.

Authors:  Renee D Stapleton; Benjamin T Suratt; Margaret J Neff; Mark M Wurfel; Lorraine B Ware; John T Ruzinski; Ellen Caldwell; Teal S Hallstrand; Polly E Parsons
Journal:  Biomarkers       Date:  2019-03-04       Impact factor: 2.658

Review 3.  Cell therapy in acute respiratory distress syndrome.

Authors:  Shahd Horie; Hector Esteban Gonzalez; John G Laffey; Claire H Masterson
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

4.  Chelerythrine Attenuates the Inflammation of Lipopolysaccharide-Induced Acute Lung Inflammation Through NF-κB Signaling Pathway Mediated by Nrf2.

Authors:  Lu Fan; Ye Fan; Li Liu; Weiwei Tao; Xin Shan; Yu Dong; Lin Li; Sen Zhang; Hanqing Wang
Journal:  Front Pharmacol       Date:  2018-09-26       Impact factor: 5.810

Review 5.  Novel approaches to metabolic assessment and structured exercise to promote recovery in ICU survivors.

Authors:  Jeroen Molinger; Amy M Pastva; John Whittle; Paul E Wischmeyer
Journal:  Curr Opin Crit Care       Date:  2020-08       Impact factor: 3.687

Review 6.  Preemptive Mechanical Ventilation Based on Dynamic Physiology in the Alveolar Microenvironment: Novel Considerations of Time-Dependent Properties of the Respiratory System.

Authors:  Gary Nieman; Joshua Satalin; Penny Andrews; Kailyn Wilcox; Hani Aiash; Sarah Baker; Michaela Kollisch-Singule; Maria Madden; Louis Gatto; Nader Habashi
Journal:  J Trauma Acute Care Surg       Date:  2018-08-17       Impact factor: 3.313

7.  Towards Reliable ARDS Clinical Decision Support: ARDS Patient Analytics with Free-text and Structured EMR Data.

Authors:  Emilia Apostolova; Amit Uppal; Jessica E Galarraga; Ioannis Koutroulis; Tim Tschampel; Tony Wang; Tom Velez
Journal:  AMIA Annu Symp Proc       Date:  2020-03-04

8.  Fraxin Alleviates LPS-Induced ARDS by Downregulating Inflammatory Responses and Oxidative Damages and Reducing Pulmonary Vascular Permeability.

Authors:  Xiaohong Ma; Xiangyong Liu; Jiali Feng; Dong Zhang; Lina Huang; Dongxiao Li; Liang Yin; Lan Li; Xiao-Zhi Wang
Journal:  Inflammation       Date:  2019-10       Impact factor: 4.092

9.  Shikonin inhibits myeloid differentiation protein 2 to prevent LPS-induced acute lung injury.

Authors:  Yali Zhang; Tingting Xu; Zheer Pan; Xiangting Ge; Chuchu Sun; Chun Lu; Hongjin Chen; Zhongxiang Xiao; Bing Zhang; Yuanrong Dai; Guang Liang
Journal:  Br J Pharmacol       Date:  2018-01-25       Impact factor: 8.739

10.  RAB26-dependent autophagy protects adherens junctional integrity in acute lung injury.

Authors:  Weijie Dong; Binfeng He; Hang Qian; Qian Liu; Dong Wang; Jin Li; Zhenghua Wei; Zi Wang; Zhi Xu; Guangyu Wu; Guisheng Qian; Guansong Wang
Journal:  Autophagy       Date:  2018-07-26       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.